Bellevue Group AG Purchases 100,000 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Bellevue Group AG raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 3.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 3,071,615 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the quarter. Celldex Therapeutics comprises about 1.7% of Bellevue Group AG’s portfolio, making the stock its 16th largest holding. Bellevue Group AG’s holdings in Celldex Therapeutics were worth $104,404,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of CLDX. Novo Holdings A S acquired a new position in Celldex Therapeutics during the second quarter worth $31,458,000. Point72 Asset Management L.P. boosted its stake in shares of Celldex Therapeutics by 51.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,937,991 shares of the biopharmaceutical company’s stock worth $71,725,000 after buying an additional 654,194 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Celldex Therapeutics by 19.8% in the 1st quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock valued at $153,215,000 after acquiring an additional 604,251 shares in the last quarter. Marshall Wace LLP increased its position in shares of Celldex Therapeutics by 53.3% in the second quarter. Marshall Wace LLP now owns 1,377,868 shares of the biopharmaceutical company’s stock valued at $50,995,000 after acquiring an additional 479,068 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock worth $45,017,000 after acquiring an additional 321,325 shares in the last quarter.

Celldex Therapeutics Stock Down 1.6 %

Shares of CLDX stock opened at $27.44 on Friday. Celldex Therapeutics, Inc. has a 52 week low of $22.93 and a 52 week high of $53.18. The company has a 50-day simple moving average of $28.81 and a 200 day simple moving average of $34.43.

Insider Transactions at Celldex Therapeutics

In other news, CEO Anthony S. Marucci bought 11,500 shares of the stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the purchase, the chief executive officer now owns 40,284 shares in the company, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.80% of the company’s stock.

Wall Street Analyst Weigh In

CLDX has been the topic of several recent analyst reports. Wells Fargo & Company raised Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, November 20th. Citigroup started coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.